The Ron Lanton Report

Hosted by Ron Lanton III, Esq., Senior Partner of Lanton, Lanton & Sosa Law, PLLC, The Ron Lanton Report is an editorial interview series featured in Pharmaceutical Executive and BioPharm International.

The Report examines the business, policy and commercial decisions shaping healthcare and life sciences. Ron speaks with executives, health economists and industry leaders about investment, biotechnology, drug pricing, market access, technology and commercialization.

Season 2 (Ongoing)

Episode 2 | November 16, 2026: Ossium Health's Bone Marrow Bank. CEO Kevin Caldwell discusses bone marrow access, cell therapy and infrastructure.

Episode 1 | October 26, 2026: A Conversation with Dr. Nadine Zawadzki. Healthcare economics, drug pricing and the measurement of value.

Season 1 (Complete)

Episode 6 | September 3, 2026: What Are We Doing This All For? Melanie Whittington discusses healthcare innovation and patient value.

Episode 5 | July 29, 2026: The Human Bottleneck. Workforce challenges in healthcare and life sciences.

Episode 4 | June 10, 2026: From Innovation to Infrastructure. Healthcare investment, operational scale and technology.

Episode 3 | April 24, 2026: Where Innovations Happen. Geography, international trade and capital.

Episode 2 | March 20, 2026: When Policy Becomes a Capital Event. Regulation and investment decisions.

Episode 1 | February 27, 2026: Is Healthcare Consolidation Reaching Its Limits? Healthcare consolidation, contracting, distribution and global commercial strategy.

Explore More

Find additional interviews and commentary in the Pharmaceutical Executive archive and the BioPharm International archive.

Related LL&S Practice Areas

Investors & Capital | Pharmaceutical Law | Biotechnology Law | Market Access & Pricing | Technology Law | LL&S Insights

The Report is an editorial platform distinct from the firm's legal services. Its content is informational and does not constitute legal advice.